Turkes A, Nott J, Turkes A O, Griffiths K
Tenovus Institute for Cancer Research, University of Wales College of Medicine, Cardiff, U.K.
Am J Clin Oncol. 1988;11 Suppl 2:S77-9. doi: 10.1097/00000421-198801102-00019.
Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) have been evaluated in patients with prostatic cancer. All patients, who participated in a phase III trial (n = 110), had disseminated disease and received first line endocrine treatment of either orchidectomy or a monthly injection of a depot luteinizing hormone-releasing hormone analogue (Zoladex). Serum samples were analyzed for PSA and PAP at 0, 3, 6, and 12 months and patients were clinically assessed at 6 and 12 months. At diagnosis, 72 and 97% of all patients had elevated PAP and PSA concentrations (greater than 4 ng/ml), respectively. Patients with progressive disease had significantly higher PSA and PAP levels at both assessments. A small number of patients in the "complete remission" group had both PSA and PAP levels within the normal range after 3 months of treatment. Similarly, both PSA and PAP levels steadily declined in the group of patients who had partial regression of the disease. The patients with stable disease, however, had a significant rise only in their PSA levels at the 12-month assessment. This data suggest that PSA is more sensitive than PAP in those patients who have a "slow progression" of the disease.
前列腺癌患者已接受前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）评估。所有参与III期试验（n = 110）的患者均患有播散性疾病，并接受了一线内分泌治疗，即睾丸切除术或每月注射一次长效促黄体生成素释放激素类似物（戈舍瑞林）。在0、3、6和12个月时分析血清样本中的PSA和PAP，并在6和12个月时对患者进行临床评估。诊断时，所有患者中分别有72%和97%的PAP和PSA浓度升高（大于4 ng/ml）。疾病进展的患者在两次评估时的PSA和PAP水平均显著更高。“完全缓解”组中的少数患者在治疗3个月后PSA和PAP水平均在正常范围内。同样，疾病部分消退的患者组中PSA和PAP水平均稳步下降。然而，疾病稳定的患者在12个月评估时仅PSA水平显著升高。该数据表明，在疾病“进展缓慢”的患者中，PSA比PAP更敏感。
